![](https://www.benzinga.com/events/small-cap/wp-content/themes/small-cap/images/icons8-equity-security-100.png)
Bright Minds Biosciences
Bright Minds (FRA:BMB) is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
![](https://www.benzinga.com/events/small-cap/wp-content/themes/small-cap/images/icons8-administrator-male-100.png)
CEO
Bright Minds
Mr. McDonald is an entrepreneur and former Investment Banker. Prior to BMB, he served on the management team at a TSX-listed gold mining company. In that capacity, McDonald developed and implemented the corporate strategy as it relates to M&A and capital markets resulting in a $160 million sale within one year.
![](https://www.benzinga.com/events/small-cap/wp-content/themes/small-cap/images/icons8-administrator-male-100.png)
Vice President of Discovery & Co-Founder
Bright Minds
Dr Gideon Shapiro, trained as an organic chemist at University of North Carolina, University of California Berkeley and the Federal Institute of Technology (ETH) is a seasoned drug hunter. His 30+ year professional career is lined with a record of achievement in drug discovery, development and drug program management.